– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE-DMD to treat serious conditions like Duchenne muscular dystrophy – – March 17, 2026 virtual webinar ...

First experimental observation of matter-wave diffraction in a short-lived electron-positron atom using a graphene-based diffraction grating. (Nanowerk News) One of the discoveries that fundamentally ...

A Boxed Warning was included in the prescribing information highlighting the risk of serious liver injury and acute liver failure. The Food and Drug Administration (FDA) has approved new safety ...

A pulse of light sets the tempo in the material. Atoms in a crystalline sheet just a few atoms thick begin to move—not randomly, but in a coordinated rhythm, twisting and untwisting in sync like ...

Duchenne muscular dystrophy (DMD) causes muscle weakness that becomes more severe over time. While there is no cure, treatments can help slow the progression and manage symptoms and complications.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non ...

Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...

There is no cure for DMD, but treatments can slow the progression of the disease and help improve quality of life. Duchenne muscular dystrophy (DMD) is a chronic condition that causes a gradual loss ...

Tailwind Capital has made an investment in DMD Systems Recovery, a Tempe, Arizona-based IT asset disposition solutions provider. No financial terms were disclosed. The capital infusion will be used by ...

After an unconventional public display of disapproval, the FDA has made a stunning reversal on Sarepta Therapeutics’ Elevidys, recommending that Duchenne muscular dystrophy (DMD) patients who can walk ...

The U.S. FDA has granted Precision Biosciences Inc.’s PBGENE-DMD orphan drug designation for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD uses two complementary Arcus nucleases ...

Sarepta Therapeutics has temporarily suspended use of the gene therapy Elevidys in non-ambulatory patients with Duchenne muscular dystrophy (DMD) after a second patient taking the drug died from acute ...